Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15181)	1/10/2005 1:53:20 PM
From: quidditch	Read Replies (1) \| Respond to of 52153

AMLN@JPM: listened to most of the webcast--hoping for April (PDUFA date) approval of exenatide and launch with combined LLY and AMLN sales force.... Q&A inferred note of interest: when asked about the sufficiency of cash to bring to fruition all of the clinical trials planned and in process and whether there were plans for an offering, the rep responded that AMLN was at $300m (as I recall) at y.e., and that, plus "the course of business opportunities that will unfold" (words to that effect) should be adequate and that no plans for an offering were currently contemplated. To me that meant that they are optimistic on exenatide approval and, possibly, partner deals are in the works for other candidates. Diabetes is not a therapeutic area that I'm familiar with so I can't really offer any intelligent comment. quid